CMN Weekly (20 December 2024) - Your Weekly CRISPR...
CMN Weekly
Dec. 20, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Avectas
Main focus: Next-generation delivery technology for gene editing
Company stage: Pre-clinical
Diseases: Cancer
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: Dublin, Ireland
Website: https://avectas.com/
Partners: ONK Therapeutics
Avectas develops its proprietary SOLUPORE® technology to genetically engineer T cells and natural killer (NK) cells to enable the next generation of gene-modified cell therapies. The company has established a collaboration with ONK Therapeutics, however, it yet has to disclose any proprietary or partnered therapeutic programmes.
